[go: up one dir, main page]

ZA200306333B - Bifunctional fusion proteins with Glucocerebrosidase activity. - Google Patents

Bifunctional fusion proteins with Glucocerebrosidase activity.

Info

Publication number
ZA200306333B
ZA200306333B ZA200306333A ZA200306333A ZA200306333B ZA 200306333 B ZA200306333 B ZA 200306333B ZA 200306333 A ZA200306333 A ZA 200306333A ZA 200306333 A ZA200306333 A ZA 200306333A ZA 200306333 B ZA200306333 B ZA 200306333B
Authority
ZA
South Africa
Prior art keywords
fusion proteins
bifunctional fusion
glucocerebrosidase activity
glucocerebrosidase
activity
Prior art date
Application number
ZA200306333A
Other languages
English (en)
Inventor
Silke Schumacher
Stephen Gillies
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200306333B publication Critical patent/ZA200306333B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200306333A 2001-01-18 2003-08-14 Bifunctional fusion proteins with Glucocerebrosidase activity. ZA200306333B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101056 2001-01-18

Publications (1)

Publication Number Publication Date
ZA200306333B true ZA200306333B (en) 2004-11-17

Family

ID=8176235

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306333A ZA200306333B (en) 2001-01-18 2003-08-14 Bifunctional fusion proteins with Glucocerebrosidase activity.

Country Status (13)

Country Link
US (1) US20040043457A1 (xx)
EP (1) EP1392826A2 (xx)
JP (1) JP2004525621A (xx)
KR (1) KR20030067755A (xx)
CN (1) CN1630720A (xx)
BR (1) BR0116803A (xx)
CA (1) CA2435037A1 (xx)
HU (1) HUP0401300A3 (xx)
MX (1) MXPA03006294A (xx)
NO (1) NO20033247D0 (xx)
PL (1) PL362394A1 (xx)
WO (1) WO2002057435A2 (xx)
ZA (1) ZA200306333B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
HK1038882A1 (zh) * 1998-04-15 2002-04-04 利思进药品公司 通过共同给予血管生成抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
ATE368475T1 (de) * 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
BR0207854A (pt) * 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
EP1706428B1 (en) * 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP4937132B2 (ja) * 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したil−7変種
US8658174B2 (en) 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PT1966238E (pt) * 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
US8748567B2 (en) * 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
MX2011011044A (es) * 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011107991A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
ES2774190T3 (es) 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2943361A1 (en) * 2014-03-28 2015-10-01 New York University Fgf23 fusion proteins
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3650539A4 (en) * 2017-07-07 2021-08-18 Hanmi Pharm. Co., Ltd. NEW THERAPEUTIC ENZYMATIC FUSION PROTEIN AND ASSOCIATED USE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6475486B1 (en) * 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1998022577A1 (en) * 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
ATE223229T1 (de) * 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
AU2001238346A1 (en) * 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline

Also Published As

Publication number Publication date
NO20033247L (no) 2003-07-17
MXPA03006294A (es) 2003-09-16
EP1392826A2 (en) 2004-03-03
US20040043457A1 (en) 2004-03-04
JP2004525621A (ja) 2004-08-26
BR0116803A (pt) 2004-02-17
KR20030067755A (ko) 2003-08-14
WO2002057435A3 (en) 2003-12-24
PL362394A1 (en) 2004-11-02
HUP0401300A3 (en) 2005-06-28
HUP0401300A2 (hu) 2004-09-28
CA2435037A1 (en) 2002-07-25
NO20033247D0 (no) 2003-07-17
WO2002057435A2 (en) 2002-07-25
CN1630720A (zh) 2005-06-22

Similar Documents

Publication Publication Date Title
ZA200306333B (en) Bifunctional fusion proteins with Glucocerebrosidase activity.
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
ZA200105484B (en) Polypeptide variants with altered effector function.
MXPA01012970A (es) Gamma-carbolinas fusionadas de heterociclo sustituido.
ZA200200477B (en) 2-pyrazolin-5-ones.
GB0009093D0 (en) Goggles assembly
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200206172B (en) Fusion protein having enhanced in vivo activity of erythropoietin.
ZA200201829B (en) New phenylpiperazines.
MXPA03009167A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
ZA200108646B (en) Electrodes.
ZA200203707B (en) Pharmaceutical combinations.
GB9913437D0 (en) Fusion proteins
MXPA03009204A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
MXPA02001506A (es) Unidad de boton.
AU2002357891A8 (en) Dtat fusion toxin
ZA200200263B (en) Drive.
MXPA03001951A (es) Pirroliminas y pirazoliminas fusionadas substituidas.
ZA992018B (en) Banners.
GB0029720D0 (en) I.S machine7544232001
ZA200204581B (en) Nitro-sulfobenzamides.
IL148549A0 (en) Subunit optimized fusion proteins
ZA200003284B (en) Cutting element with stress reduction.
ZA98834B (en) 2-substituted-1-acyl-1,2-dihydroquinoline derivatives.
ZA991391B (en) Novel herbicides.